Diagnosis, Treatment and Prevention of Age-Related Macular Degeneration

In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of au...

Full description

Saved in:
Bibliographic Details
Other Authors: Kodjikian, Laurent (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_81005
005 20220506
003 oapen
006 m o d
007 cr|mn|---annan
008 20220506s2022 xx |||||o ||| 0|eng d
020 |a books978-3-0365-3929-4 
020 |a 9783036539300 
020 |a 9783036539294 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-0365-3929-4  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
100 1 |a Kodjikian, Laurent  |4 edt 
700 1 |a Kodjikian, Laurent  |4 oth 
245 1 0 |a Diagnosis, Treatment and Prevention of Age-Related Macular Degeneration 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (246 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of autonomy and a decrease in patients' quality of life. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a aflibercept monotherapy 
653 |a polypoidal choroidal vasculopathy 
653 |a neovascular age-related macular degeneration 
653 |a good baseline visual acuity 
653 |a ForeseeHome AMD Monitoring System® 
653 |a AREDS2-HOME study 
653 |a age-related macular degeneration 
653 |a exudation 
653 |a optical coherence tomography angiography 
653 |a anti-vascular endothelial growth factor 
653 |a brolucizumab 
653 |a epithelial tear 
653 |a optical coherence tomography 
653 |a Sorsby's fundus dystrophy 
653 |a Sorsby 
653 |a hereditary retinal dystrophy 
653 |a choroidal neovascularisation 
653 |a macular neovascularization 
653 |a anti-VEGF treatment 
653 |a long-term FU 
653 |a treatment outcome 
653 |a emerging treatment 
653 |a neovascular age-related macular degeneration (nAMD) 
653 |a Vascular Endothelial Growth Factor (VEGF) 
653 |a cataract surgery 
653 |a clinical trials 
653 |a real-world evidence 
653 |a AMD 
653 |a oct-angiography 
653 |a fellow eye 
653 |a choriocapillaris 
653 |a quiescent macular neovascularization 
653 |a ranibizumab 
653 |a aflibercept 
653 |a anti-VEGF 
653 |a visual acuity 
653 |a reading acuity 
653 |a disease activity 
653 |a treatment change 
653 |a treat and extend 
653 |a switch therapy 
653 |a retina 
653 |a choroidal neovascularization 
653 |a angiogenesis 
653 |a meteorin 
653 |a therapeutic innovation 
653 |a prevention 
653 |a nutrients 
653 |a lifestyle 
653 |a treatment-naive 
653 |a anti-vascular endothelial growth factor 
653 |a cardiovascular risk factors 
653 |a arterial hypertension 
653 |a macula-off rhegmatogenous detachment 
653 |a superficial perifoveal capillary plexus 
653 |a retinal deep perifoveal capillary plexus 
653 |a identification 
653 |a risk 
653 |a Delphi 
653 |a STARS® 
653 |a food supplement 
653 |a bevacizumab 
653 |a meta-analysis 
653 |a meta-regression 
653 |a n/a 
653 |a age-related macular degeneration (AMD) 
653 |a comparative therapies 
653 |a effectiveness 
653 |a intravitreal anti-vascular endothelial growth factor 
653 |a treat-and-extend 
653 |a pro re nata regimen 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/5347  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/81005  |7 0  |z DOAB: description of the publication